Padron Eric, Komrokji Rami, List Alan F
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Clin Adv Hematol Oncol. 2014 Mar;12(3):172-8.
Chronic myelomonocytic leukemia (CMML) is an aggressive malignancy characterized by peripheral monocytosis and ineffective hematopoiesis. It has been historically classified as a subtype of the myelodysplastic syndromes (MDSs) but was recently demonstrated to be a distinct entity with a distinct natural history. Nonetheless, clinical practice guidelines for CMML have been inferred from studies designed for MDSs. It is imperative that clinicians understand which elements of MDS clinical practice are translatable to CMML, including which evidence has been generated from CMML-specific studies and which has not. This allows for an evidence-based approach to the treatment of CMML and identifies knowledge gaps in need of further study in a disease-specific manner. This review discusses the diagnosis, prognosis, and treatment of CMML, with the task of divorcing aspects of MDS practice that have not been demonstrated to be applicable to CMML and merging those that have been shown to be clinically similar.
慢性粒单核细胞白血病(CMML)是一种侵袭性恶性肿瘤,其特征为外周血单核细胞增多和无效造血。它在历史上一直被归类为骨髓增生异常综合征(MDS)的一种亚型,但最近被证明是一种具有独特自然病程的独立疾病实体。尽管如此,CMML的临床实践指南是从针对MDS的研究中推断出来的。临床医生必须了解MDS临床实践中的哪些要素可转化应用于CMML,包括哪些证据是来自CMML特异性研究,哪些不是。这有助于采用基于证据的方法治疗CMML,并以疾病特异性方式识别需要进一步研究的知识空白。本综述讨论了CMML的诊断、预后和治疗,旨在区分尚未证明适用于CMML的MDS实践方面,并合并那些已证明在临床上相似的方面。